COL6A2

COL6A2 encodes the alpha-2 chain of type VI collagen, a microfibrillar extracellular matrix protein whose assembly, secretion, and network formation are essential for skeletal muscle integrity, cardiac development, and cell-matrix signaling. The C-terminal globular domain, particularly the C2 subdomain, is dispensable for triple-helix formation but critical for microfibrillar assembly; nonsense, missense, and splice-site mutations in COL6A2 cause collagen VI myopathies (Ullrich congenital muscular dystrophy and Bethlem myopathy) through mechanisms including nonsense-mediated mRNA decay, impaired secretion, and dominant-negative interference with matrix network formation (PMID:12218063, PMID:20106987, PMID:16075202, PMID:38544966). COL6A2 physically interacts with integrin β1 to activate Wnt/β-catenin signaling and epithelial-mesenchymal transition in carcinoma cells, and its overexpression promotes proliferation, migration, and immune evasion in glioblastoma (PMID:41323784, PMID:38860406, PMID:41074600). Co-overexpression of COL6A2 with DSCAM cooperatively produces congenital heart defects in mice through perturbation of adhesion and cardiac hypertrophy gene programs (PMID:22072978).

1. 1991 Medium

   Establishing the genomic organization of COL6A2 resolved that the alpha-1 and alpha-2 chain genes form a tightly linked cluster on chromosome 21q22.3, providing the physical framework for understanding coordinate regulation and disease genetics.

   Evidence Pulsed-field gel electrophoresis, somatic cell hybrid mapping, and fiber-FISH in human cells

   PMID:1676701 PMID:8575781

   Open questions at the time

   • Functional significance of head-to-tail arrangement not determined
   • Whether coordinate transcriptional regulation occurs from the shared locus was not tested
2. 2002 High

   Demonstrating that COL6A2 nonsense mutations trigger nonsense-mediated mRNA decay and that residual mutant mRNA produces abnormal microfibrils unable to form extensive networks established the C-terminal globular domain as essential for microfibrillar assembly but not triple-helix formation.

   Evidence Northern blot, mRNA quantification, and immunofluorescence of collagen VI matrix deposition in patient and carrier fibroblasts

   PMID:12218063

   Open questions at the time

   • Structural basis for why the C-terminal domain is required for network formation was not resolved
   • Contribution of individual C-terminal subdomains (C1 vs C2) not dissected
3. 2005 Medium

   Identification of a deep intronic splice mutation generating cryptic transcripts degraded by NMD showed that loss of COL6A2 mRNA quantity, not dominant-negative protein, can be the primary disease mechanism in Ullrich CMD.

   Evidence RT-PCR and Northern blot of patient fibroblast RNA with genomic DNA sequencing

   PMID:16075202

   Open questions at the time

   • Quantitative threshold of COL6A2 mRNA needed for functional matrix assembly not defined
   • Only one patient studied
4. 2010 High

   Dissecting recessive C-globular missense mutations showed that the C1 subdomain (E624K) permits chain assembly but disrupts fibril morphology, while the C2 subdomain (R876S) prevents triple-helical molecule assembly altogether; the C2a splice variant can partially compensate, refining the domain-specific roles in collagen VI biogenesis.

   Evidence Patient fibroblast analysis, stable transfection of mutant constructs, secretion assays, electron microscopy of microfibrils

   PMID:20106987

   Open questions at the time

   • Structural mechanism by which C2a variant rescues assembly not resolved
   • Whether compensatory C2a expression is clinically relevant in vivo not established
5. 2010 Medium

   Discovery that deep intronic deletions can silence one COL6A2 allele expanded the mutational spectrum of collagen VI myopathies beyond coding and canonical splice-site mutations.

   Evidence Custom CGH array with RNA monoallelic transcription confirmation in patient cells

   PMID:20302629

   Open questions at the time

   • Mechanism of transcriptional silencing by intronic deletion not characterized
   • Whether regulatory elements within intron 1A control COL6A2 expression was not tested
6. 2011 High

   Demonstrating that COL6A2 and DSCAM must be co-overexpressed to produce congenital heart defects established a genetic interaction linking collagen VI to cardiac adhesion and hypertrophy pathways beyond its structural ECM role.

   Evidence Combinatorial overexpression screen in Drosophila heart, mouse cardiac overexpression, H9C2 cell transcriptional profiling

   PMID:22072978

   Open questions at the time

   • Direct physical interaction between COL6A2 and DSCAM not shown
   • Whether this cooperativity is relevant to Down syndrome-associated heart defects in humans not confirmed
7. 2012 Medium

   Antisense oligonucleotide-mediated exon skipping selectively degraded the mutant COL6A2 transcript and restored collagen VI secretion and ECM network formation, providing proof-of-concept for allele-specific therapeutic silencing of dominant COL6A2 mutations.

   Evidence 2'-O-methyl phosphorothioate antisense oligonucleotide treatment of patient fibroblasts with collagen VI secretion and immunofluorescence readouts

   PMID:22992134

   Open questions at the time

   • In vivo efficacy and delivery not tested
   • Applicability to other dominant COL6A2 mutations not demonstrated
8. 2024 Medium

   A polyadenylation signal deletion in the COL6A2 3'-UTR caused alternative last exon usage and sarcolemma-specific collagen VI deficiency, revealing that post-transcriptional 3'-end processing defects produce tissue-selective rather than global collagen VI loss.

   Evidence Whole-genome sequencing, RNA sequencing of patient muscle, immunofluorescence for collagen VI localization

   PMID:38544966

   Open questions at the time

   • Why the deficiency is sarcolemma-specific rather than global is mechanistically unexplained
   • Single family reported
9. 2024 Medium

   Direct luciferase-validated targeting of COL6A2 by miR-3189-3p, whose expression is epigenetically silenced by PRC2-mediated H3K27me3, linked COL6A2 upregulation to GBM proliferation, migration, and EMT, establishing COL6A2 as a functional effector in glioblastoma malignancy.

   Evidence Luciferase reporter assay with mutagenesis, ChIP for H3K27me3, functional cell assays in GBM cells

   PMID:38860406

   Open questions at the time

   • In vivo relevance in GBM animal models not shown
   • Whether COL6A2 is a driver or passenger in glioblastoma progression not resolved
10. 2025 Medium

    Identification of a physical interaction between COL6A2 and integrin β1 that activates Wnt/β-catenin signaling to drive EMT in renal cell carcinoma defined a specific signaling axis through which extracellular COL6A2 promotes tumor invasion.

    Evidence Co-immunoprecipitation, integrin blockade, Wnt/β-catenin activator rescue experiments in ccRCC cells

    PMID:41323784

    Open questions at the time

    • Co-IP not validated by reciprocal IP or structural data
    • Whether integrin β1 interaction occurs in non-cancer physiological contexts not tested
    • In vivo tumor model validation absent
11. 2025 Medium

    COL6A2 silencing in GBM cells restored dendritic cell activation and effector immune cell infiltration, revealing an immunosuppressive function of COL6A2 in the tumor microenvironment.

    Evidence CyTOF immune profiling and functional proliferation/invasion assays upon COL6A2 knockdown in glioblastoma cells

    PMID:41074600

    Open questions at the time

    • Mechanism by which COL6A2 suppresses dendritic cell activation not identified
    • In vivo immunological validation not performed

• The structural basis for how the C2 subdomain directs microfibrillar network assembly, the in vivo relevance of integrin β1–Wnt/β-catenin signaling in physiological collagen VI functions, and whether COL6A2's immunomodulatory and cardiac roles represent distinct or overlapping mechanisms remain unresolved.
• No atomic-resolution structure of the COL6A2 C-terminal domain in the context of the trimer
• No in vivo validation of integrin β1-mediated signaling axis
• Mechanism of immune evasion mediated by COL6A2 not molecularly defined